Trial
NCT04043845
ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Dana-Farber Cancer Institute
Collaborators
Eli Lilly and Company
Condition
Chronic Lymphocytic Leukemia
Intervention
Ibrutinib
Why stopped
Business development reasons.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-02-05